Free Trial
Matthew Keller

Matthew Keller Analyst Performance

Equity Research Associate at HC Wainwright

Matthew Keller is a stock analyst at HC Wainwright in the medical sector, covering 6 publicly traded companies. Over the past year, Matthew Keller has issued 8 stock ratings, including and buy recommendations. While full access to Matthew Keller's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Matthew Keller's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
8 Last 0 Years
Buy Recommendations
100.00% 8 Buy Ratings
Companies Covered
6 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy100.0%8 ratings
Hold0.0%0 ratings
Sell0.0%0 ratings

the majority (100.0%) have been Buy recommendations.

Best & Worst Calls

This analyst does not have any ratings with enough history to determine best and worst calls.

Exchange Coverage

ExchangePercentageCount
NASDAQ
100.0% of companies on NASDAQ
6 companies

Matthew Keller, an analyst at HC Wainwright, currently covers 6 companies listed on , with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
6 companies
100.0%

Matthew Keller of HC Wainwright specializes in stock coverage within the Medical sector.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
3 companies
50.0%
MED - DRUGS
3 companies
50.0%

Matthew Keller's Ratings History at HC Wainwright

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
9/30/2025Reiterated Rating$4.17$31.00Buy
FibroGen, Inc stock logo
FGEN
FibroGen
9/24/2025Reiterated Rating$12.22$43.00Buy
InflaRx N.V. stock logo
IFRX
InflaRx
9/2/2025Initiated Coverage$1.60$6.00Buy
Gyre Therapeutics, Inc. stock logo
GYRE
Gyre Therapeutics
8/26/2025Initiated Coverage$8.20$18.00Buy
Phio Pharmaceuticals Corp. stock logo
PHIO
Phio Pharmaceuticals
8/15/2025Reiterated Rating$2.19$14.00Buy
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
8/14/2025Reiterated Rating$3.69$6.00Buy
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
8/12/2025Boost Price Target$4.10$31.00Buy
FibroGen, Inc stock logo
FGEN
FibroGen
8/7/2025Reiterated Rating$7.99$43.00Buy